doi:10.1093/aje/kwf018
21 Weight loss stabilized by about 36 weeks, similar to trials with other weight-loss agents, 22, 23 was maintained over 2 years and was significantly greater with liraglutide 2.4/3.0 mg than with orlistat
AHK-Cu Dosage Protocols: Research Model Comparison Key Takeaways AHK-Cu protocols studied in research settings range from 0.252mg daily via subcutaneous injection, with mid-range doses (0.751.5mg) most commonly extrapolated from preclinical models
The fuel for this energy is a molecule called NAD+
Results are based on self-reported data from ~10,000 DosePop patients on personalized treatment plans, including compounded GLP-1based therapies and clinician consultations
McCulloch typically uses 1,5002,000 mg/day clinical protocols often adjust from research doses based on patient presentation, tolerability, and the broader supplement strategy